Table 2 Univariate analyses of potential prognostic factors for overall survival (OS)
Factors | OS at 1 year (%) | OS at 2 years (%) | OS at 5 years (%) | p-value |
|---|---|---|---|---|
Age | ||||
65–74 years | 72 | 53 | 22 | |
75–84 years | 78 | 58 | 24 | |
≥ 85 years | 60 | 30 | 30 | 0.60 |
Gender | ||||
Female | 79 | 71 | 30 | |
Male | 72 | 48 | 21 | 0.10 |
ECOG score | ||||
0–1 | 72 | 54 | 25 | |
2–3 | 77 | 46 | - | 0.20 |
Charlson Comorbidity Index | ||||
≤ 5 | 64 | 64 | 29 | |
> 5 | 76 | 48 | 19 | 0.20 |
Clinical tumor classification (cT) | ||||
1 | 50 | - | - | |
2 | 83 | 50 | 17 | |
3 | 74 | 56 | 27 | |
4 | 60 | 33 | 17 | 0.70 |
Clinical lymph node classification (cN) | ||||
Nodal negative (N0) | 75 | 54 | 18 | |
Nodal positive (N +) | 73 | 52 | 24 | 0.80 |
Tumor stage (AJCC) | ||||
1–3 | 71 | 52 | 23 | |
4a | 80 | 52 | 19 | 0.70 |
Localization of the primary tumor | ||||
15–32 cm distance from the incisors | 76 | 66 | 32 | |
33 cm distance from the incisors until gastro-esophageal junction | 72 | 48 | 19 | 0.20 |
Administration of full-dose RT | ||||
yes | 33 | 17 | - | |
no | 76 | 55 | 23 | 0.10 |
Cumulative dose of RT (EQD2) | ||||
≤ 50 Gy | 72 | 49 | 31 | |
> 50 Gy | 75 | 57 | 17 | 0.70 |
Administration of non-modified, full-dose chemotherapy | ||||
yes | 81 | 66 | 36 | |
no | 68 | 45 | 18 | 0.17 |
Treatment concept | ||||
Neoadjuvant CRT followed by surgical resection | 90 | 69 | 45 | |
Definitive RT / CRT | 63 | 43 | 14 | 0.004 |